Objective
To assess treatment efficacy using spectral domain optical coherence tomography (SD-OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide (ACZ) and weight management and placebo and weight management in eyes with mild visual loss.
Design
Randomized double-masked control clinical trial of acetazolamide (ACZ) plus weight management compared with placebo plus weight management in previously untreated III in subjects withmild visual field loss.
Subjects
Eighty-nine (43 ACZ, 46 placebo treated) of 165 subject meeting entry criteria for the IIHTT.
Methods
Subjects had perimetry, papilledema grading (Frisén method), high and low contrast visual acuity, and SD-OCT imaging at study entry, 3 and 6 months. Study eye (worse perimetric mean deviation, PMD) results were used for most analyses.
Main Outcome Measures
Retinal nerve fiber layer (RNFL), total retinal thickness (TRT), optic nerve volume (ONHV), and retinal ganglion cell layer (GCL) measurements were derived using 3-D segmentation.
Results
Study entry OCT values were similar in both treatment groups. At 6 months, the ACZ group had greater reduction than the placebo group for RNFL (175 μm vs 89 μm, p=0.001), TRT (220 μm vs 113 μm, p=0.001), and ONHV (4.9 mm3 vs 2.1 mm3, p=0.001). The RNFL (p=0.01), TRT (p=0.003), and ONHV (p=0.002) also showed less swelling in subjects who lost ≥ 6% of study entry weight. GCL thinning was minor in ACZ (3.6 μm) and placebo (2.1 μm, p =0.06) groups. The RNFL, TRT, and ONHV showed moderate correlations (r=0.48-0.59, p≤0.0001) with Frisén grade. The 14 eyes with GCL thickness <5th percentile of controls had worse PMD (p=0.001) than study eyes with GCL ≥ 5th percentile.
Conclusions
RNFL, TRT, and ONH volume measurements of swelling due to papilledema in IIH are effectively improved with ACZ and weight loss. In contrast to the strong correlation at baseline, OCT measures at 6 months show only moderate correlations with papilledema grade.